Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Exelixis (EXEL – Research Report), American Well (AMWL – Research Report) and Merck & Company (MRK – Research Report).
Exelixis (EXEL)
In a report released yesterday, Jason Gerberry from Bank of America Securities maintained a Buy rating on Exelixis, with a price target of $27.00. The company’s shares closed last Friday at $21.11.
According to TipRanks.com, Gerberry is a 1-star analyst with an average return of
Exelixis has an analyst consensus of Moderate Buy, with a price target consensus of $26.21.
See Insiders’ Hot Stocks on TipRanks >>
American Well (AMWL)
In a report released yesterday, David Larsen from BTIG maintained a Hold rating on American Well. The company’s shares closed last Friday at $1.09, close to its 52-week low of $0.93.
According to TipRanks.com, Larsen has 0 stars on 0-5 stars ranking scale with an average return of
Currently, the analyst consensus on American Well is a Hold with an average price target of $2.43, representing a 131.4% upside. In a report issued on October 19, Wells Fargo also reiterated a Hold rating on the stock with a $2.00 price target.
Merck & Company (MRK)
Bank of America Securities analyst Geoff Meacham reiterated a Buy rating on Merck & Company yesterday and set a price target of $130.00. The company’s shares closed last Friday at $102.67.
According to TipRanks.com, Meacham is a 4-star analyst with an average return of
Currently, the analyst consensus on Merck & Company is a Strong Buy with an average price target of $124.79, a 24.8% upside from current levels. In a report released yesterday, Citi also reiterated a Buy rating on the stock with a $130.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on EXEL:
